NVLX: New results Even Better
Today, is a cool day for 2 reasons. First, today’s date is 10/11/12. Nice and consecutive.
Plus, we are issuing an update on Nuvilex (OTCQB – NVLX)for the first time in a while. The Company released results of a second Phase 2 trial for pancreatic cancer that we believe are even better than the first one.
I know investors are ambivalent or downright dismissive of news and so the stock has gone nowhere recently. However, I defy anyone to read through results and compare the progress to the current market cap, and tell me the stock is not incredibly cheap.
Savvy investors and traders will pounce while the rest of the Street ignores NVLX and they could be well rewarded as more milestone events occur.
LOR: The Next Major Oncology Player
Today, we are initiating coverage of Lorus Therapeutics, Inc. (LOR.TO, OTCQB - LRUSF) a biopharma that is focused on novel anticancer drugs. The Company may be the most undervalued sleeper in the entire biotech segment. LOR has multiple anti-cancer therapies on 2 separate platforms, with several cancer indications, representing billions of dollars in market potential. The patent portfolio is vast, with 29 patents awarded and 19 pending.
TRTC: Changing the Agriculture Industry
Good afternoon! Today we are initiating coverage of Terra Tech Corp. (OTCBB – TRTC) a company that is changing the way produce is grown and distributed. Terra Tech has quietly emerged as one of the country’s most important agriculture companies. Management is revolutionizing and helping drive the growth of indoor agriculture cultivation through its proprietary cultivation and production systems, while enhancing distribution of locally-owned produce from specialty stores to mass market retail chains. Terra Tech just announced a landmark partnership that will serve as a model for future transactions and it could result in millions in annual revenue and a 51% ownership for Terra Tech. Management has engaged a vertical integration strategy via M&A and strategic partnerships that could ultimately drive TRTC stock to the $2.00 level. This strategy should propel revenue from $3M in 2012 to roughly $30M in 2 years. With a huge top-line growth rate and a nearly 20% operating margin, we rate TRTC Speculative Buy.
Next Big Profitable Nutraceutical
Today we are initiating coverage of Creative Edge Nutrition (OTCPK – FITX) a leading nutritional supplement company focused on the active lifestyle consumer segment. The Company is profitable and just acquired one of the most popular brands in the business that generates $10M annually in sales. Due to the vertical integration and roll-up strategy, we believe FITX could generate $60M in FY13. Our target is $0.35
SMAA: A Car Dealer’s Dream
Today we are initiating coverage of SMA Alliance (OTCPK – SMAA). Earlier this month, SMA acquired Cars.net, a major industry site that lists inventory from nearly 14,000 dealers and boasts nearly 5 million monthly unique visitors. This deal, plus the signing of a letter of intent with a large automotive manufacturer for nationwide Internet marketing placement services could place it near the top of the automotive e-marketing platform food chain. Plus, the pending IPO of industry player AutoTrader should have a favorable impact on SMA as well. Our target is $1.50.
WRAP Your Email Around This
Today we are initiating coverage of WrapMail, which has a proprietary platform that enables users to transform their emails into branding and marketing tools. We liked the Company so much we signed up as a client. The founder just bought 700,000 in the open market so he put his money where his mouth is. WRAP could be an amazing and widely used branding tool for any organization. Our long term target is $0.60.
LBGO: A Compelling Valuation
We are reiterating our rating on Liberty Gold (OTCBB – LBGO). Stock is off recently which makes it a great buy at these levels especially considering the recent news and strong investor accumulation of gold-based equities.
CUBV is a Category Killer
We are initiating coverage of Cuba Beverage Company, which could turn out to be the next great energy drink. Unlike its competitors, like Red Bull, et al, CUBV produces an all-natural drink with no caffeine or taurine that is priced a full dollar less than a Red Bull can, the market leader. There are a number of milestones in the near term in terms of new distribution and customer partners with the who’s who of retail. Plus, with 50% margins, the Company should earn $0.03 next year. It closed yesterday at $0.086 and our target is $0.75, which is just 25x FY13E EPS.
Gold Leader Primed to Shine
Looking to strike gold? Look no further. We are initiating coverage of Liberty Gold Corp. (OTCBB - LBGO) today with a Speculative Buy rating and $3.00 price objective. The Company has huge assets in Arizona and Alaska. The Arizona properties have a number of claims, including on four mines successfully mined in the past. Moreover, these properties have an estimated potential valuation of $16.7 billion. Plus, The potential net present value (NPV) for geological exploration targets of a recently commenced exploration is in the order of $1 billion - $3 billion. Success is even further bolstered by the management team, which has a long history of success building and operating top-tier, publicly traded mining companies.
The Only Way to Treat Cancer
We are initiating coverage of Immunovative, Inc. (OTCBB – IMUN) today with a Speculative Buy rating and $1.70 price objective. Here is the big takeaway. The company is the sole licensee of another Firm’s products. The flagship product has shown in Phase I/II clinical trials to basically kill metastatic breast cancer tumors with no chemotherapy or lethal toxicity. It is an amazing immunotherapy method that has nearly 20 patents granted and another 20 pending. Partner institutions include the Mayo Clinic as there are 10 indications for other cancers.
<< Start < Prev 41 42 43 44 45 Next > End >>

Page 41 of 45